Screener
Madrigal Pharmaceuticals, Inc. MDGL Business Segments — Professional Fees
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProfessionalFees.
The source filing: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050845
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Facility related and other internal expenses(1) | (1,486) | (1,656) | (2,669) | (2,781) |
| Selling, general and administrative: | ||||
| Compensation and benefit-related expenses | (80,321) | (52,504) | (163,926) | (100,865) |
| Stock-based compensation | (28,382) | (19,805) | (54,439) | (35,521) |
| Professional fees and other external expenses | (148,996) | (109,841) | (280,248) | (197,855) |
| Facility related and other internal expenses(1) | (31,676) | (14,708) | (59,283) | (30,493) |
| Other segment (expense) income(2) | (1,631) | 4,921 | (3,299) | 10,994 |
| Net loss | $(57,939) | $(42,281) | $(152,330) | $(115,519) |
Item 1. Financial Statements (Unaudited):
FAQ
- What is Madrigal Pharmaceuticals, Inc.'s business segments — professional fees?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported business segments — professional fees of $149M in Q2 2026.
- What does business segments — professional fees mean?
- This includes payments to third-party consultants, legal counsel, auditors, and other external service providers. These expenses are often variable and reflect the company's reliance on external expertise for specialized projects.
Ask your AI about Madrigal Pharmaceuticals, Inc.'s business segments — professional fees.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude